Total Payments
$142,484
2024 Payments
$70,991
Companies
5
Transactions
77
Payment Breakdown by Category
Consulting$134,214 (94.2%)
Research$6,000 (4.2%)
Travel$1,503 (1.1%)
Food & Beverage$736.99 (0.5%)
Education$29.83 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $134,214 | 49 | 94.2% |
| Unspecified | $6,000 | 4 | 4.2% |
| Travel and Lodging | $1,503 | 7 | 1.1% |
| Food and Beverage | $736.99 | 14 | 0.5% |
| Education | $29.83 | 3 | 0.0% |
Payments by Type
General
$136,484
73 transactions
Research
$6,000
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Mirum Pharmaceuticals, Inc. | $105,406 | 41 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $12,849 | 10 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $12,596 | 11 | $0 (2024) |
| Gilead Sciences, Inc. | $11,632 | 14 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $70,991 | 21 | Mirum Pharmaceuticals, Inc. ($65,571) |
| 2023 | $27,598 | 17 | Mirum Pharmaceuticals, Inc. ($22,638) |
| 2022 | $19,398 | 10 | Mirum Pharmaceuticals, Inc. ($17,198) |
| 2021 | $6,125 | 5 | Alexion Pharmaceuticals, Inc. ($4,375) |
| 2020 | $9,295 | 6 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($4,000) |
| 2019 | $7,203 | 14 | Gilead Sciences, Inc. ($5,202) |
| 2018 | $1,875 | 4 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($1,846) |
All Payment Transactions
77 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| Category: Alagille syndrome | ||||||
| 10/17/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| Category: Alagille syndrome | ||||||
| 10/15/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| Category: Alagille syndrome | ||||||
| 10/08/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| Category: Alagille syndrome | ||||||
| 10/08/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| Category: Alagille syndrome | ||||||
| 08/12/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: NEPHROLOGY | ||||||
| 08/03/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Food and Beverage | Cash or cash equivalent | $116.46 | General |
| Category: Alagille syndrome | ||||||
| 08/03/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Food and Beverage | Cash or cash equivalent | $69.64 | General |
| Category: Alagille syndrome | ||||||
| 08/02/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Consulting Fee | Cash or cash equivalent | $5,200.00 | General |
| Category: Alagille syndrome | ||||||
| 08/02/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Consulting Fee | Cash or cash equivalent | $5,200.00 | General |
| Category: Alagille syndrome | ||||||
| 08/02/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Travel and Lodging | Cash or cash equivalent | $683.40 | General |
| Category: Alagille syndrome | ||||||
| 08/02/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Consulting Fee | Cash or cash equivalent | $385.00 | General |
| Category: Alagille syndrome | ||||||
| 08/02/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Food and Beverage | Cash or cash equivalent | $143.48 | General |
| Category: Alagille syndrome | ||||||
| 08/02/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Travel and Lodging | Cash or cash equivalent | $130.00 | General |
| Category: Alagille syndrome | ||||||
| 08/02/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Food and Beverage | Cash or cash equivalent | $49.25 | General |
| Category: Alagille syndrome | ||||||
| 08/02/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Food and Beverage | Cash or cash equivalent | $40.34 | General |
| Category: Alagille syndrome | ||||||
| 08/02/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Travel and Lodging | Cash or cash equivalent | $26.50 | General |
| Category: Alagille syndrome | ||||||
| 08/02/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Food and Beverage | Cash or cash equivalent | $11.52 | General |
| Category: Alagille syndrome | ||||||
| 05/24/2024 | Alexion Pharmaceuticals, Inc. | KANUMA (Biological) | Consulting Fee | Cash or cash equivalent | $3,420.00 | General |
| Category: Rare Disease | ||||||
| 03/12/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEPHROLOGY | ||||||
| 03/07/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Consulting Fee | Cash or cash equivalent | $43,890.00 | General |
| Category: Alagille syndrome | ||||||
| 12/19/2023 | Gilead Sciences, Inc. | Vemlidy (Drug) | Consulting Fee | Cash or cash equivalent | $2,710.00 | General |
| Category: HBV | ||||||
| 12/19/2023 | Alexion Pharmaceuticals, Inc. | KANUMA (Biological) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Rare Disease | ||||||
| 09/29/2023 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| Category: Alagille syndrome | ||||||
| 09/20/2023 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| Category: Alagille syndrome | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3B, TWO-PART, MULTICENTER, ONE YEAR RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF THE SAFETY, PHARMACOKINETICS, TOLERABILITY, AND EFFICACY OF TOLVAPTAN FOLLOWED BY A TWO YEAR OPEN-LABEL EXTENSION IN CHILDREN AND ADOLESCENT SUBJECTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) | Otsuka Pharmaceutical Development & Commercialization, Inc. | $4,000 | 3 |
| A PHASE 3B, TWO-PART, MULTICENTER, ONE YEAR RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF THE SAFETY, PHARMACOKINETICS, TOLERABILITY, AND EFFICACY OF TOLVAPTAN FOLLOWED BY A TWO YEAR OPEN-LABEL EXTENSION IN CHILDREN AND ADOLESCENT SUBJECTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE ADPKD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $2,000 | 1 |
About Dr. William Balistreri, M.D
Dr. William Balistreri, M.D is a Pediatric Gastroenterology healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952338378.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Balistreri, M.D has received a total of $142,484 in payments from pharmaceutical and medical device companies, with $70,991 received in 2024. These payments were reported across 77 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($134,214).
Ad
Practice Information
- Specialty Pediatric Gastroenterology
- Other Specialties Pediatric Gastroenterology
- Location Cincinnati, OH
- Active Since 06/28/2006
- Last Updated 01/30/2018
- Taxonomy Code 2080P0206X
- Entity Type Individual
- NPI Number 1952338378
Products in Payments
- Livmarli (Drug) $91,546
- KANUMA (Biological) $6,870
- TOLVAPTAN (Drug) $6,596
- Kanuma (Drug) $5,979
- JYNARQUE (Drug) $4,000
- Vemlidy (Drug) $2,710
- SAMSCA (Drug) $2,000
- (820) Cholbam (Drug) $0.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Gastroenterology Doctors in Cincinnati
Ajay Kaul, M.d, M.D
Pediatric Gastroenterology — Payments: $54,840
Pediatric Gastroenterology $54,840
Dr. Akihiro Asai, M.d., Ph.d, M.D., PH.D
Pediatric Gastroenterology — Payments: $30,394
Pediatric Gastroenterology $30,394
Vincent Mukkada, Md, MD
Pediatric Gastroenterology — Payments: $28,118
Pediatric Gastroenterology $28,118
Khalil El-Chammas, M.d, M.D
Pediatric Gastroenterology — Payments: $16,719
Pediatric Gastroenterology $16,719
Samuel Kocoshis, M.d, M.D
Pediatric Gastroenterology — Payments: $14,994
Pediatric Gastroenterology $14,994
Jose' Garza, M.d, M.D
Pediatric Gastroenterology — Payments: $14,003
Pediatric Gastroenterology $14,003